Start the conversation
Back in October, I did something crazy.
That's when I told the paid-up members of my Radical Technology Profits trading service to buy a small-cap biotech stock.
Here's why that move was a bit nuts.
At the time, it looked like Hillary Clinton would soon enter in the White House and clamp down on drug prices – and so the biopharmaceutical sector was deeply out of favor.
Turns out, however, our crazy bet paid off.
Despite his campaign rhetoric, President Donald Trump has pulled back from his own fiery rhetoric about drug-price caps.
That helped pushed biotech and drug stocks into a big uptrend.
And my paid-up members made peak gains of 116% – in just over eight months.
Today, things have changed – and investing in biopharma stocks is generally seen as a smart move. However, that means a lot of these shares have been bid up, and your best move is to buy big winners at deep discounts.
But to do that, you have to know how to find those deals.
Today I'll show you how you can, too.
And I'll reveal the three best biotech bargains out there right now.
All three have triple-digit gain potential…
Not One, but Two D.C. Catalysts
I hate to look to Washington for help when it comes to finding tech stocks you can use to get on the Road to Wealth.
But I'll take it when it comes our way.
Besides the seeming end of grousing about drug prices, biopharma stocks are gaining ground from another big catalyst out of Washington.
The White House is now talking about speeding up the U.S. Food and Drug Administration approval process.
That would be huge.
You see, hundreds of drugs are in FDA trials. It now takes an average 10 years and $1 billion to get a drug from discovery to market.
So, anything that gets the hundreds of drugs now in FDA trials out faster and cheaper is good news for biopharma investors – not to mention doctors and patients seeking new and effective treatments.
No wonder the sector is on fire once again.
The iShares Nasdaq Biotechnology ETF (Nasdaq: IBB) is up 11% since it hit a three-month low on May 30. Those gains are better than nine times greater than the S&P 500's return of 1.2% over the period.
So, now that we have some proof for the sector's rebound, it's time to dig up those biotech bargains.
Remember that 116%-gains-in-eight-months winner I told you about before?
I didn't do so just to brag, but to demonstrate to you that I've got a knack – a system – for finding undervalued biotech shares. And I see a similar setup occurring right now with three great pharmaceutical leaders that are priced for a big move up.
Here's how I know: each is selling at a big discount from its peer group.
I base that on the fact that the tech-centric Nasdaq 100 is trading at about 21 times the forward price-to-earnings ratio (forward P/E), a key gauge of earnings growth roughly a year out. And based on their forward P/Es, these three biotech bargains are trading at "fire sale" prices.
Take a look…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.